Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RHYNAL-XL syrup is an oral combination formulation containing cetirizine hydrochloride (an antihistamine) and ambroxol hydrochloride (a mucolytic agent). Developed and marketed by Minova Life Sciences in India, it is indicated for the treatment of allergic respiratory conditions associated with bronchospasm and excessive mucus secretion, such as allergic rhinitis, chronic spontaneous urticaria, and mild asthma. Cetirizine acts as a selective histamine H1 receptor antagonist to alleviate allergic symptoms like sneezing, runny nose, and itching. Ambroxol acts as a secretolytic agent, thinning mucus and facilitating its clearance by stimulating surfactant production and blocking voltage-gated sodium channels (specifically Nav1.8) to reduce airway irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambroxol + cetirizine.